Anumana’s AI algorithm for cardiac amyloidosis gets FDA breakthrough nod
Related Articles
Anumana, Inc. announced that it has received funding from Boston Scientific Corporation, Matrix Capital Management, Mayo Clinic, Endowment Arm, Matrix Management Corporation, NTT Venture Capital
MarketScreener: Anumana, Inc. announced that it has received a round of funding from new investor, Boston Scientific Corporation on April 24, 2025. The transaction included participation from returning investors, Matrix…April 24, 2025
Anumana Acquires NeuTrace, Establishing a Comprehensive Electrophysiology Deep-Learning Development Platform and Product Pipeline
Anumana acquires NeuTrace, a medical technology company advancing novel in-procedure AI applications for electrophysiology (EP)November 07, 2022
How Mayo Clinic is using AI to spot hidden heart conditions
Advisory Board: Mayo Clinic last month released a study suggesting that an artificial intelligence (AI) algorithm could be used to better diagnose a certain heart condition called low ejection fraction—one step…May 31, 2021
Anumana partners with Novartis for AI-driven heart disease detection
Medical Device Network: Health technology company Anumana and Novartis Pharmaceuticals Corporation have entered a partnership to use artificial intelligence (AI) for the detection of heart diseases. Under the multi-year collaboration,…July 13, 2022